As of January 23, 2025, Renalytix (RNLX) has a market cap of $22.548 million USD. According to our data, Renalytix is ranked No.8558 in global market value.
Year | Market Cap | %Change |
---|---|---|
Dec 06, 2024 | $22.55 M |
-63.92%
|
Dec 29, 2023 | $32.36 M |
-79.14%
|
Dec 30, 2022 | $0.16 B |
-88.24%
|
Dec 31, 2021 | $1.32 B |
-0.63%
|
Dec 31, 2020 | $1.33 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
CareDx
CDNA
|
$1.24 B |
-0.000 M
|
USA
|
Natera
NTRA
|
$22.70 B |
-0.001 M
|
USA
|
Veracyte
VCYT
|
$3.34 B |
-0.000 M
|
USA
|
Exact Sciences
EXAS
|
$10.14 B |
0.000 M
|
USA
|
Guardant Health
GH
|
$5.83 B |
0.000 M
|
USA
|
Fulgent Genetics
FLGT
|
$0.52 B |
-0.000 M
|
USA
|
Myriad Genetics
MYGN
|
$1.12 B |
-0.000 M
|
USA
|
NeoGenomics
NEO
|
$1.86 B |
0.000 M
|
USA
|
Adaptive Biotechnologies
ADPT
|
$1.18 B |
0.000 M
|
USA
|
Personalis
PSNL
|
$0.47 B |
0.000 M
|
USA
|
OncoCyte
OCX
|
$33.00 M |
0.000 M
|
USA
|
Market Cap | = | RNLX Stock Price | * | RNLX Shares Outstanding |
= | $0.14 | * | 82.96 M | |
= | $22.55 M |